TJU is currently recruiting patients for Rituximab Treatment of SSc-PAH

ASCO1 Study

ASC01: Rituximab for Treatment of SSc-PAH
Sponsored by the National Institutes of Health (NIH) through its Division of Allergy, Immunology, & Transplantation (DAIT) of the National Institute of Allergy & Infectious Disease (NIAID)
Conducted by Dr. Sandra Weibel
Thomas Jefferson University
Tele: 215-955-6591     Email:
We are looking for patients who …     
·       have systemic sclerosis (scleroderma)
·       have pulmonary arterial hypertension (PAH) which
              ~ is not due to pulmonary fibrosis &
              ~ has been diagnosed less than 5 years ago
·       have been on stable PAH treatment (prostanoid &/or endothelin receptor antagonist &/or PDE-5 inhibitor) for the last 3 months
·       are 18-75 years old
Primary Hypothesis: rituximab-treated subjects will demonstrate improvement or stabilization compared to the placebo-treated subjects in pulmonary vascular resistance from baseline to 24 weeks post-treatment.

Screening by Clinical Trial Site




Rituximab plus Standard Therapy


Placebo plus Standard Therapy


Monthly Follow-Up Visits for One Year

Study Design:

Published: 11-23-2011

Close Window